Finch Therapeutics Group (Finch Therapeutics Group) LT-Debt-to-Total-Asset : 0.51 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Finch Therapeutics Group LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Finch Therapeutics Group's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.51.

Finch Therapeutics Group's long-term debt to total assets ratio increased from Dec. 2022 (0.30) to Dec. 2023 (0.51). It may suggest that Finch Therapeutics Group is progressively becoming more dependent on debt to grow their business.

Finch Therapeutics Group LT-Debt-to-Total-Asset Historical Data

The historical data trend for Finch Therapeutics Group's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Finch Therapeutics Group LT-Debt-to-Total-Asset Chart

Finch Therapeutics Group Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

0.01

0.02

0.30

0.51

Finch Therapeutics Group Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial												0.30	0.42	0.44	0.48	0.51

Finch Therapeutics Group LT-Debt-to-Total-Asset Calculation

Finch Therapeutics Group's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	28.403	/	55.373
	=	0.51

Finch Therapeutics Group's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	28.403	/	55.373
	=

Finch Therapeutics Group (NAS:FNCH) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Finch Therapeutics Group LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Finch Therapeutics Group's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Finch Therapeutics Group (Finch Therapeutics Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Finch Therapeutics Group Inc (NAS:FNCH) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Inner Belt Road, Suite 400, Somerville, MA, USA, 02143

Website

https://www.finchtherapeutics.com

Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The lead product candidate is CP101 which delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection.

Executives

Jeffery A Smisek	director	1600 SMITH STREET, HQSEO, HOUSTON TX 77002
Susan E Graf	director	400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Lance E Thibault	officer: Chief Financial Officer
Matthew P. Blischak	officer: Chief Executive Officer	C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SOMERVILLE MA 02143
Joseph Vittiglio	officer: Chief Business & Legal Officer	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BLVD, SOMERVILLE MA 02145
Marc Blaustein	officer: Chief Operating Officer	C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143
Domenic J Ferrante	director	BROOKSIDE CAPITAL MANAGEMENT LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Samuel A Hamood	director	C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Joanne L. Viney	director	C/O HARPOON THERAPEUTICS, INC., 131 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Nicholas Haft	director	C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143
Christian H. Lange	director	28 HAVEMEYER PLACE, GREENWICH CT 06830
Crestovo Investor Llc	director, 10 percent owner	28 HAVEMEYER PLACE, GREENWICH CT 06830
Gregory D Perry	officer: Chief Financial Officer	C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Chris Shumway	director, 10 percent owner	28 HAVEMEYER PLACE, GREENWICH CT 06830
Zain Kassam	officer: Chief Medical Officer	C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143